NASDAQ:KRYS - Krystal Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Krystal Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $51.83 -0.43 (-0.82 %) (As of 01/21/2020 02:55 AM ET) Add Compare Today's Range$50.77Now: $51.83▼$53.4350-Day Range$47.06MA: $57.79▼$65.2352-Week Range$18.50Now: $51.83▼$66.50Volume162,803 shsAverage Volume149,954 shsMarket Capitalization$897.18 millionP/E RatioN/ADividend YieldN/ABeta1.14 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS Previous Symbol CUSIPN/A CIK1711279 Webhttp://www.krystalbio.com/ Phone412-586-5830Debt Debt-to-Equity Ratio0.01 Current Ratio54.87 Quick Ratio54.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.85 per share Price / Book6.60Profitability EPS (Most Recent Fiscal Year)($0.97) Net Income$-10,890,000.00 Net MarginsN/A Return on Equity-11.08% Return on Assets-10.70%Miscellaneous Employees37 Outstanding Shares17,310,000Market Cap$897.18 million Next Earnings Date3/10/2020 (Estimated) OptionableNot Optionable Receive KRYS News and Ratings via Email Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KRYS Rates by TradingView Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." How were Krystal Biotech's earnings last quarter? Krystal Biotech Inc (NASDAQ:KRYS) issued its quarterly earnings results on Monday, November, 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.14. View Krystal Biotech's Earnings History. When is Krystal Biotech's next earnings date? Krystal Biotech is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Krystal Biotech. What price target have analysts set for KRYS? 6 brokerages have issued twelve-month price objectives for Krystal Biotech's stock. Their forecasts range from $59.00 to $81.00. On average, they expect Krystal Biotech's share price to reach $68.75 in the next year. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Krystal Biotech. What is the consensus analysts' recommendation for Krystal Biotech? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech. What are Wall Street analysts saying about Krystal Biotech stock? Here are some recent quotes from research analysts about Krystal Biotech stock: 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (1/4/2020) 2. Cowen Inc analysts commented, "On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated." (8/15/2019) 3. Chardan Capital analysts commented, "We view the receipt of the FDA Therapy (RMAT) designation as a significant positive for the timelines on KB103. This news follows KB103 receiving the EMA Priority Medicines (PRIME) designation on 29 March. As we have noted, Krystal’s market cap is modest relative to companies with PRIME and/or RMAT/BTD designations. We again reiterate: We would not be surprised if Krystal’s market cap crosses $1 billion by 2020E. On today’s news, we update our detailed model, moving the probability of KB103 launch from 55% to 67%, leading to an increase in our 2030E KB103 sales estimate from $492.1 mm to $596.5 mm. With a reduction in our WACC from 12.4% to 11.9%, these changes lead to a 30% KRYS PT target increase, from $57.50 to $75. has demonstrated impressive wound closure data (albeit in small numbers of patients) in the GEM-1 and GEM-2 studies." (6/24/2019) 4. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our target to $38 from $32. The changes to our valuation include: (1) adjustment to base year to reflect the current NPV relative to our September 2018 initiation of coverage; and (2) increasing our projected chance of success for to 15%. We are currently leaving our projected chance of success for KB103 the same, at 25%, and await the pending clinical update this quarter." (5/24/2019) 5. William Blair analysts commented, "We continue to view the anticipated second quarter clinical update of the GEM trial as a significant near-term catalyst for shares. As we have noted previously (see our note, We See Durable Wound Closure and 30%-40% COL7A1 Expression as after reviewing the published literature, we believe that achieving roughly 30%-40% of wild-type (normal) levels of collagen VII could be sufficient to restore skin integrity and prevent skin blistering. We also believe that the presence of anchoring fibrils should be viewed qualitatively only due to its lack of direct correlation with clinical results." (5/6/2019) Has Krystal Biotech been receiving favorable news coverage? Media coverage about KRYS stock has trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Krystal Biotech. Are investors shorting Krystal Biotech? Krystal Biotech saw a decrease in short interest in December. As of December 31st, there was short interest totalling 1,470,000 shares, a decrease of 12.0% from the December 15th total of 1,670,000 shares. Based on an average daily volume of 159,700 shares, the days-to-cover ratio is presently 9.2 days. Currently, 13.6% of the company's stock are short sold. View Krystal Biotech's Current Options Chain. Who are some of Krystal Biotech's key competitors? Some companies that are related to Krystal Biotech include Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX) and Alector (ALEC). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Anavex Life Sciences (AVXL), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Axsome Therapeutics (AXSM), Momo (MOMO) and Portola Pharmaceuticals (PTLA). Who are Krystal Biotech's key executives? Krystal Biotech's management team includes the folowing people: Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)Ms. Pooja Agarwal, VP of Product Devel. (Age 40)Mr. Antony A. Riley, Chief Financial Officer (Age 51)Ms. Gloria Lin, Accounting Mang. When did Krystal Biotech IPO? (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Garnet Equity Capital Holdings Inc. (0.07%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech. Which institutional investors are selling Krystal Biotech stock? KRYS stock was sold by a variety of institutional investors in the last quarter, including Garnet Equity Capital Holdings Inc.. Company insiders that have sold Krystal Biotech company stock in the last year include Daniel Janney, Krish S Krishnan and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech. How do I buy shares of Krystal Biotech? Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $51.83. How big of a company is Krystal Biotech? Krystal Biotech has a market capitalization of $897.18 million. The company earns $-10,890,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.View Additional Information About Krystal Biotech. What is Krystal Biotech's official website? The official website for Krystal Biotech is http://www.krystalbio.com/. How can I contact Krystal Biotech? Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830. MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 212 (Vote Outperform)Underperform Votes: 219 (Vote Underperform)Total Votes: 431MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2020 by MarketBeat.com StaffFeatured Article: How do candlesticks reflect price movement?
